Monitor for future equity issuances under the expanded plan, but no near-term trading catalyst. The filing is routine and does not change the company's financial outlook.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $77.08entry
- T+1 · 6mo ago +3.07%α +3.21% · $79.45
- T+5 · 6mo ago +6.79%α +6.87% · $82.31
- T+20 · 5mo ago +13.57%α +13.88% · $87.54
- T+60 · 3mo ago +15.36%α +11.24% · $88.92
Price Chart
How similar events traded
Executive Summary
Edwards Lifesciences reported the results of its 2026 Annual Meeting, where stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program, increasing the share pool by 7 million shares to 341.5 million. All director nominees were elected, and other proposals including say-on-pay and auditor ratification passed. This is a routine administrative filing with no material financial impact.
Key Facts
- Stockholders approved Amended and Restated Long-Term Stock Incentive Compensation Program, increasing share pool by 7,000,000 shares to a total of 341,500,000 shares.
- All nine director nominees were elected with majority votes.
- Advisory vote on executive compensation passed with 424,961,639 for and 50,924,101 against.
- Ratification of PricewaterhouseCoopers as independent auditor approved with 446,283,142 for and 56,814,075 against.
- Vote on the compensation plan passed with 456,675,201 for and 19,210,539 against.
Financial Impact
No immediate financial impact; potential future dilution from increased share authorization is minimal relative to outstanding shares.
Risk Factors
- Potential dilution from future equity grants under the expanded share pool.
- No other material risks identified.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001099800-26-000028 |
| Document: 0001099800-26-000028-index-headers.html | 0001099800-26-000028 |
| Document: 0001099800-26-000028-index.html | 0001099800-26-000028 |
| Document: 0001099800-26-000028.txt | 0001099800-26-000028 |
Track record
27 reports on EW
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.94% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
- Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers